Skip to main content
v2026.11,986 entries · CC-BY 4.0

Annex 13: Investigational Medicinal Products and the CTR

Annex 13 was the traditional regulatory framework for the Good Manufacturing Practice (GMP) of Investigational Medicinal Products (IMPs) in the European Union. It has been replaced by the Clinical Trials Regulation (CTR) (EU) No 536/2014.

Written and maintained by CASRAI Editorial Board

Published

On this page

Annex 13: Investigational Medicinal Products and the CTR

Annex 13 was the traditional regulatory framework for the Good Manufacturing Practice (GMP) of Investigational Medicinal Products (IMPs) in the European Union. It has been replaced by the Clinical Trials Regulation (CTR) (EU) No 536/2014, which integrated GMP requirements for IMPs into a unified framework. This guide outlines the regulatory status and current compliance landscape for IMPs as of November 17, 2026.

What it is and who runs it

Annex 13 was formerly a part of EudraLex Volume 4, the primary set of guidelines for GMP in the EU. It provided specific instructions for the manufacturing and labeling of IMPs for clinical trials. Under the new Clinical Trials Regulation (EU) No 536/2014, the core principles of GMP for IMPs are established in the Regulation itself and in Commission Delegated Regulation (EU) 2017/1569. The regulatory framework is overseen by the national competent authorities in each EU Member State.

Eligibility

The Clinical Trials Regulation (CTR) applies to all clinical trials conducted in the European Union, regardless of where the sponsor is located, if the trial is conducted within an EU Member State. IMPs used in these trials must adhere to GMP standards.

What it requires

Compliance requires a robust Quality Management System (QMS) specifically tailored to the manufacturing of IMPs. Key requirements include:

  • Personnel: Qualified and experienced staff responsible for manufacturing and quality control.
  • Facilities: Adequate premises and equipment to ensure the quality, safety, and efficacy of the IMPs, with rigorous controls to prevent cross-contamination.
  • Documentation: Maintenance of comprehensive records, including the Investigational Medicinal Product Dossier (IMPD) or equivalent, which details the manufacturing process, quality control, and testing.
  • Labeling: IMPs must be clearly labeled according to the requirements set out in the CTR to ensure traceability, blinding where applicable, and safety information.

Application or compliance steps

  1. Establish a QMS that addresses the specific needs of IMP manufacturing.
  2. Compile all necessary data on the IMP’s manufacturing process, quality control tests, and safety data.
  3. Ensure the manufacturing facility holds the required authorization for the production of IMPs.
  4. Perform batch release testing and ensure adherence to specifications.
  5. Maintain records for audit and inspection by national competent authorities.

Typical timeline phases

  • Pre-Trial Manufacturing: Development of the manufacturing process, quality control tests, and preparation of the IMP Dossier.
  • Clinical Trial Supply: Production and packaging of the IMPs according to trial requirements.
  • Batch Release: Quality assurance review and certification of each batch before its release for clinical use.
  • Trial Conduct: Ongoing compliance with GMP requirements throughout the duration of the clinical trial.

Common mistakes

  • Documentation Failures: Incomplete or inaccurate batch records or documentation in the IMP Dossier.
  • Labeling Errors: Incorrect or non-compliant labeling of IMPs, which can compromise trial blinding or subject safety.
  • Traceability Issues: Failure to adequately track IMPs throughout the supply chain.
  • Inadequate QMS: A system that does not specifically address the unique requirements of IMP manufacturing.

For more information on the regulatory framework, see the dataset below, which summarizes related EU clinical trial programs.

Frequently asked questions

Is Annex 13 still in use?

No. Annex 13 has been replaced by the Clinical Trials Regulation (EU) No 536/2014, which now provides the regulatory framework for IMPs in the EU.

How do I ensure compliance for my IMP?

Compliance requires following the requirements of the CTR, which includes maintaining a robust QMS, preparing an IMP Dossier, ensuring your manufacturing facility is authorized, and adhering to GMP standards throughout the manufacturing process.

Sources

Data: Related EU Clinical Trial Programs and Regulations

This table compares key regulatory frameworks and guidelines governing clinical trials and Investigational Medicinal Products (IMPs) in the European Union, compiled from EU legal documents.

Related EU Clinical Trial Programs and Regulations
Program/RegulationDescriptionRelationship to IMPs
Regulation (EU) 536/2014 (CTR)Clinical Trials RegulationReplaces Annex 13 and governs trial conduct and IMP requirements.
EudraLex Volume 4GMP GuidelinesProvides detailed guidance for GMP compliance in the EU.
Good Clinical Practice (GCP)Standards for trial conductEnsures the rights, safety, and well-being of trial subjects are protected.

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Annex 13: Investigational Medicinal Products and the CTR

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →